ETF name(Code), Benchmark Index, Inception date, creation unit, Net Asset (KRW 0.1 billion), Trustee, Rule of Dividend payment, Market Price per share (KRW), iNAV per share (KRW), trading volume (share), Total Expense ratio table
ETF Name (code)
Benchmark Index
Inception date
Creation Unit
AUM (KRW)
KB RISE HealthCare Fixed Income Balanced ETF
(253290)
FnGuide HealthCare Mix Index
2016.09.23
200,000
21,220,838,678
Trustee
Market Price per share (KRW)
NAV
Trading Volume (shares)
하나은행
11,735
※ t-1 last price
11,789
135,918
authorized participant, Liquidity provider table
Total Expense Ratio
Distribution Frequency
Year 0.35%
(Designated participating company : 0.001%,
Collective investment : 0.309%,
trust : 0.02%,
General affairs : 0.02%)
Based on the business day before the interest payment date of the stocks constituting the index in June and December (occasional payment)
The FnGuide Healthcare Balanced Index is an index consisting of stock items constituting the FnGuide Healthcare Index and three KTBs constituting the MKF 3-year KTB Index. It maintains a 7:3 ratio of bonds to stocks everyday.
Name, Ticker, Number. of shares, Weight(%), market price (KRW)
No. (Number)
Name
Ticker
Number of shares
Weight(%)
Market price (KRW)
1
KTB02500-3009(25-8)
KR103503GF95
714,285,714
28.66
675,655,714
2
KTB02875-2712(24-12)
KR103501GEC6
428,571,429
18.25
430,230,857
3
RISE KTB
KR7114100001
3,850
17.26
406,887,250
4
RISE HealthCare
KR7253280002
19,141
10.9
256,967,925
5
KTB02250-2806(25-4)
KR103501GF63
142,857,143
5.95
140,251,571
6
KTB3 F 202606
KR4A65660008
0.67
2.91
68,673,368
7
Celltrion
KR7068270008
308
2.22
52,360,000
8
SAMSUNG BIOLOGICS
KR7207940008
33
1.81
42,768,000
9
Alteogen
KR7196170005
121
1.68
39,506,500
10
HLB
KR7028300002
732
1.51
35,648,400
11
Yuhan
KR7000100008
347
1.13
26,614,900
12
ABL Bio
KR7298380007
260
1.02
24,024,000
13
SCD
KR7000250001
87
0.89
21,097,500
14
LCB
KR7141080002
164
0.89
20,992,000
15
원화예금
KRD010010001
20,401,017
0.87
20,401,017
16
HanmiPharm
KR7128940004
39
0.71
16,711,500
17
SKBP
KR7326030004
170
0.66
15,623,000
18
PharmaResearch
KR7214450009
42
0.49
11,592,000
19
HANALL BIOPHARMA
KR7009420001
220
0.49
11,484,000
20
ST Pharm
KR7237690003
81
0.41
9,566,100
21
L&C BIO
KR7290650001
104
0.34
8,060,000
22
Hugel
KR7145020004
33
0.34
7,986,000
23
SKBS
KR7302440003
165
0.27
6,435,000
24
CLASSYS
KR7214150005
134
0.25
5,963,000
25
SEEGENE
KR7096530001
200
0.25
5,840,000
26
Celltrionph
KR7068760008
128
0.23
5,459,200
27
Pharmicell
KR7005690003
349
0.19
4,578,880
28
GC Biopharma Corp.
KR7006280002
34
0.18
4,192,200
29
CHA Biotech
KR7085660009
337
0.17
3,912,570
30
HK inno.N
KR7195940002
89
0.16
3,657,900
31
Hanmi Science
KR7008930000
127
0.16
3,771,900
32
ORUM
KR7475830006
59
0.16
3,687,500
33
CHONGKUNDANG
KR7185750007
49
0.15
3,469,200
34
DAEWOONG PHARM
KR7069620003
28
0.14
3,312,400
35
DongKook Pharm
KR7086450004
147
0.11
2,606,310
36
MedyTox
KR7086900008
34
0.11
2,689,400
37
ILDONG PHARM
KR7249420001
131
0.1
2,458,870
38
WONTECH
KR7336570007
270
0.09
2,022,300
39
i-SENS
KR7099190001
130
0.09
2,186,600
40
Daewoong
KR7003090008
123
0.09
2,054,100
41
ShinpoongPharm
KR7019170000
206
0.08
1,798,380
42
HLBPHARMA
KR7047920004
174
0.08
1,910,520
43
CUREXO
KR7060280005
181
0.08
1,889,640
44
DENTIUM
KR7145720009
41
0.08
1,824,500
45
EuBio
KR7206650004
194
0.08
1,804,200
46
SELVAS AI
KR7108860008
148
0.06
1,326,080
47
Binex
KR7053030003
179
0.06
1,449,900
48
BioPlus
KR7099430001
264
0.05
1,239,480
49
Humedix
KR7200670008
37
0.04
969,400
50
Huons Global
KR7084110006
34
0.04
933,300
Investment notice
- The information provided on this website is based on reliable sources, but its accuracy and completeness are not guaranteed.
- Financial investment products are not protected by the Korea Deposit Insurance Corporation in accordance with the Depositor Protection Act, and a loss of investment principal may occur, which belongs to the investor.
- Past performance does not guarantee future profits.
- In the case of a collective investment scheme that invests in foreign securities, asset values may be lost due to risks caused by market, political, and economic conditions in the target country.
- Derivatives may lose all or a significant portion of the investment principal in a short period of time due to high price volatility, and there is a risk that the counterparty may not be able to fulfill the terms of the contract when investing in over-the-counter derivatives.
- Before investing, be sure to read the investment prospectus and contract recommendation document regarding the investment subject, redemption method, and fee.